Quisovalimab
Based on 1 publication(s) in Google Scholar
Quisovalimab (AVTX-002) is a human-derived monoclonal antibody against LIGHT (TNFSF14). Quisovalimab binds to LIGHT, blocks the signal transduction activity of LIGHT, reduces circulating LIGHT levels and attenuates pro-inflammatory effects. Quisovalimab can be used in research related to Crohn's disease, COVID-19-associated pneumonia and acute respiratory distress syndrome comorbidity.
For research use only. We do not sell to patients.
- Purity: 98.73%
- CAS No.: 2427667-03-4
- Molecular Weight:144.32 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Quisovalimab
More
Biological Activity
Human IgG4 kappa
Human
TNFSF14
Quisovalimab exhibits favorable pharmacokinetic, pharmacodynamic and safety profiles[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG4 kappa
ELISA, FACS, Functional assay
Chemical Information
-
CAS No. 2427667-03-4
-
Appearance Liquid
-
Molecular Weight 144.32 kDa
-
Color Colorless to light yellow
-
SMILES
[Quisovalimab]
-
Synonyms
AVTX-002; AEVI 002; SAR 252067; CERC-002; MDGN-002
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
Purity & Documentation
-
Data Sheet (257 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Mousa RS, et al. TNFSF14 (LIGHT) in intestinal inflammation: balancing immune activation and resolution in IBD. Front Immunol. 2025;16:1657071. Published 2025 Sep 15. [Content Brief]
[2]. Ware CF, et al. Realigning the LIGHT signaling network to control dysregulated inflammation. J Exp Med. 2022;219(7):e20220236. [Content Brief]
[3]. Perlin DS, et al. Levels of the TNF-Related Cytokine LIGHT Increase in Hospitalized COVID-19 Patients with Cytokine Release Syndrome and ARDS. mSphere. 2020;5(4):e00699-20. Published 2020 Aug 12. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Quisovalimab Related Classifications
Cat. No.: HY-P99810
Powered by Bioz
- Quisovalimab
- 2427667-03-4
- AVTX-002
- AEVI 002
- SAR 252067
- CERC-002
- MDGN-002
- AVTX002
- AVTX 002
- AEVI002
- AEVI 002
- AEVI-002
- SAR252067
- SAR 252067
- SAR-252067
- CERC002
- CERC 002
- CERC-002
- MDGN002
- MDGN 002
- MDGN-002
- SARS-CoV
- anti-TNF therapy
- ARDS
- TNFSF14
- Crohn’s disease
- COVID-19-associated pneumonia
- LIGHT
- acute respiratory distress syndrome
- Inhibitor
- inhibitor
- inhibit